Showing results (141-150 of 259) with videos related to
Sort By:
Pageof 26
Blood|July 21, 2021
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemiaSteven P Treon, Kirsten Meid, Zachary R Hunter, et al.Clinical Lymphoma & Myeloma|October 13, 2007
Novel agents in the treatment of Waldenström's macroglobulinemiaSteven P Treon, Evdoxia Hatjiharissi, Xavier Leleu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2021
Venetoclax in Previously Treated Waldenström MacroglobulinemiaJorge J Castillo, John N Allan, Tanya Siddiqi, et al.Blood|May 31, 2002
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.ACS Medicinal Chemistry Letters|November 20, 2020
Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell LymphomaJohn M Hatcher, Guang Yang, Li Wang, et al.British Journal of Haematology|January 11, 2005
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical applicationToshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, et al.Frontiers in Immunology|January 24, 2022
Cleavage-Mediated Regulation of Myd88 Signaling by Inflammasome-Activated Caspase-1Monika Avbelj, Iva Hafner-Bratkovič, Duško Lainšček, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)Scott J Rodig, Jeremy S Abramson, Geraldine S Pinkus, et al.Seminars in Oncology|April 30, 2003
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerationsSteven P Treon, Abigail Kelliher, Beverly Keele, et al.Blood|August 21, 2008
Thalidomide and rituximab in Waldenstrom macroglobulinemiaSteven P Treon, Jacob D Soumerai, Andrew R Branagan, et al.Pageof 26